

CITATION REPORT

List of articles citing

Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes

DOI: 10.2119/2006-00090.nakamura
Molecular Medicine, 2007, 13, 185-9.

Source: <https://exaly.com/paper-pdf/42530609/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
117	sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. 2007 , 39, 899-902		26
116	Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. 2007 , 8, 1138-43		62
115	Polyphenols and inflammation: basic interactions. 2007 , 10, 724-8		143
114	RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. <i>Molecular Medicine</i> , 2007 , 13, 625-35	6.2	126
113	Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. 2007 , 7, 188-90		50
112	Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. 2008 , 76, 52-6		76
111	Severity of diabetic microvascular complications is associated with a low soluble RAGE level. 2008 , 34, 392-5		77
110	Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. 2008 , 17, 983-96		100
109	Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. 2008 , 47, 1554-8		41
108	Dietary fructose and the metabolic syndrome. 2008 , 24, 204-9		142
107	Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. 2009 , 4, 167-177		32
106	Soluble forms of RAGE in human diseases: clinical and therapeutical implications. <i>Current Medicinal Chemistry</i> , 2009 , 16, 940-52	4.3	140
105	Hyperglycemia and glycation in diabetic complications. 2009 , 11, 3071-109		264
104	Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients. 2009 , 58, 421-5		17
103	Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. 2009 , 29, 180-9		83
102	Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. 2009 , 87, 235-47		170
101	Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. 2009 , 52, 705-14		58

100	Glycation endproducts, soluble receptor for advanced glycation endproducts and cytokines in diabetic and non-diabetic pregnancies. 2009 , 61, 175-82	26
99	Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. 2009 , 120, 119-22	36
98	Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. 2009 , 42, 802-7	53
97	Exercise and muscle dysfunction in COPD: implications for pulmonary rehabilitation. 2009 , 117, 281-91	36
96	The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoints in type 2 diabetes mellitus. 2009 , 20, 253-60	50
95	Serum level of pigment epithelium derived factor (PEDF) is an independent determinant of resting heart rate in Japanese subjects. 2009 , 136, 245-7	13
94	Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. 2009 , 58, 1624-8	42
93	RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. 2009 , 7, 17	386
92	AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis. 2009 , 42, 302-4	39
91	Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. 2009 , 205, 544-8	110
90	Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients. 2009 , 20, 267-73	24
89	RAGE: a novel biological and genetic marker for vascular disease. 2009 , 116, 621-37	130
88	Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2009 , 16, 845-58	4-3 84
87	Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. 2010 , 59, 64-9	19
86	Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. 2010 , 79, 1379-86	130
85	Effects of glycation of the model food allergen ovalbumin on antigen uptake and presentation by human dendritic cells. 2010 , 129, 437-45	87
84	Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. 2010 , 57, 55-61	42
83	Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy. 2010 , 2010, 170393	14

82	Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy. 2010 , 11, 1468-82	61
81	Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. 2010 , 59, 2027-32	92
80	sRAGE induces human monocyte survival and differentiation. 2010 , 185, 1822-35	55
79	The N-(carboxymethyl)lysine-RAGE axis: putative implications for the pathogenesis of obesity-related complications. 2010 , 5, 839-854	9
78	Serum levels of pigment epithelium-derived factor (PEDF) are an independent determinant of insulin resistance in patients with essential hypertension. 2010 , 143, 96-8	29
77	Matrix metalloproteinase-9 activity is associated to oxidative stress in patients with acute coronary syndrome. 2010 , 143, 98-100	13
76	Plasma sRAGE is independently associated with high sensitivity C-reactive protein in type 2 diabetes without coronary artery disease. 2010 , 87, e19-22	4
75	Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. 2010 , 209, 173-7	65
74	The different isoforms of the receptor for advanced glycation end products are modulated by pharmacological agents. 2010 , 45, 143-53	18
73	Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: calprotectin and IL-6 changes do not correspond to sRAGE changes. 2010 , 70, 294-9	12
72	RAGE and cardiovascular disease. 2011 , 16, 486-97	55
71	Targeted reduction of advanced glycation improves renal function in obesity. 2011 , 80, 190-8	83
70	Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. 2011 , 32, 763-77	344
69	Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). 2011 , 216, 192-8	51
68	Soluble receptor for advanced glycation end products is associated with in-stent restenosis in patients with type 2 diabetes with drug-eluting coronary stents. 2011 , 22, 12-7	6
67	Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. 2011 , 120, 81-9	57
66	Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. 2011 , 54, 2669-77	60
65	Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. 2011 , 44, 601-4	56

64	Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. 2011 , 20, 1430-8	60
63	Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. 2011 , 71, 3582-9	59
62	Studies on Renal Disorders. 2011 ,	3
61	Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE)--intra- and inter-individual variability in chronic hemodialysis patients. 2012 , 72, 296-303	1
60	Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients. 2012 , 23, 85-90	14
59	RAGE processing in chronic airway conditions: involvement of Staphylococcus aureus and ECP. 2012 , 129, 1515-21.e8	26
58	AGE/RAGE as a Mediator of Insulin Resistance or Metabolic Syndrome: Another Aspect of Metabolic Memory?. 2012 ,	
57	Non-surgical periodontal therapy with and without subgingival minocycline administration in patients with poorly controlled type II diabetes: a randomized controlled clinical trial. 2012 , 16, 599-609	27
56	Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. 2013 , 16, 344-51	10
55	High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina. 2013 , 2013, 863036	22
54	Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. 2013 , 14, 18899-924	32
53	Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects. 2013 , 10, 380-2	21
52	Effect of Ne-carboxymethyllysine on oxidative stress and the glutathione system in beta cells. 2014 , 1, 973-980	9
51	Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients. 2014 , 30, 693-700	17
50	Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. 2014 , 6, 880-93	22
49	Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients. 2014 , 14, 45-51	1
48	Diabetes mellitus potentiates diffuse large B-cell lymphoma via high levels of CCL5. 2014 , 10, 1231-6	5
47	Effect of statins on the serum soluble form of receptor for advanced glycation end-products and its association with coronary atherosclerosis in patients with angina pectoris. 2014 , 4, 47-52	7

46 Glycation, Inflammation and RAGE. **2015**, 27-41

45	Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease. 2015 , 24, 75-80	46
44	Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. 2015 , 38, 1891-7	48
43	Effect of diet-derived advanced glycation end products on inflammation. 2015 , 73, 737-59	85
42	Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease. 2016 , 81, 403-418	56
41	What does Cigarette Smoking do to the Circulating Level of Soluble Receptor for Advanced Glycation End Products?. 2016 , 25, 137-8	3
40	Is Elevated Levels of Serum Soluble Receptor for Advanced Glycation End Products Harmful in Cigarette Smokers?. 2016 , 25, 199-202	1
39	Low Endogenous Secretory Receptor for Advanced Glycation End-Products Levels Are Associated With Inflammation and Carotid Atherosclerosis in Prediabetes. 2016 , 101, 1701-9	29
38	Serum and Aqueous Concentrations of Inflammatory Markers in Diabetic Macular Edema. 2016 , 24, 549-54	20
37	Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children. 2017 , 30, 63-69	5
36	Can soluble receptor for advanced glycation end-product (sRAGE) levels in blood be used as a predictor of cardiovascular diseases?. 2017 , 266, 223-225	3
35	Effects of ferric citrate supplementation on advanced glycation end products in a rat model of streptozotocin/nicotinamide-induced diabetes. 2017 , 61, 1600753	1
34	Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. 2018 , 83, 120-127	33
33	Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients. 2018 , 2018, 1347432	14
32	Carnosine and advanced glycation end products: a systematic review. 2018 , 50, 1177-1186	36
31	The Role of Advanced Glycation End Products in Diabetic Vascular Complications. 2018 , 42, 188-195	126
30	Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease. 2018 , 29, 712-722	41
29	Advanced Glycation, Diabetes, and Dementia. 2018 , 169-193	3

28	Increased levels of soluble Receptor for Advanced Glycation End-products (RAGE) are associated with a higher risk of mortality in frail older adults. 2019 , 48, 696-702		16
27	Hepatic Fat Content and Liver Enzymes Are Associated with Circulating Free and Protein-Bound Advanced Glycation End Products, Which Are Associated with Low-Grade Inflammation: The CODAM Study. 2019 , 2019, 6289831		7
26	Studies on mechanism of free N ^ε (carboxymethyl)lysine-induced toxic injury in mice. 2019 , 33, e22322		5
25	Caloric restriction improves the redox homeostasis in the aging male rat heart even when started in middle-adulthood and when the body weight is stable. 2019 , 20, 127-140		12
24	Cellular and Molecular Aspects of Blood Cell-Endothelium Interactions in Vascular Disorders. 2020 , 21,		9
23	Pathological Role of Receptor for Advanced Glycation End Products in Calcified Aortic Valve Stenosis. 2020 , 9, e015261		4
22	Glycation-induced protein aggregation and cellular toxicity: an insight into the disease realm of high dietary sugar intake. 2020 , 251-275		
21	Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects. 2020 , 2020, 3818196		78
20	Effects of the age/rage axis in the platelet activation. 2021 , 166, 1149-1161		2
19	Higher sRAGE Levels Predict Mortality in Frail Older Adults with Cardiovascular Disease. 2021 , 67, 202-210		1
18	The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes. 2021 , 42, 101958		8
17	Dietary advanced glycation end-products elicit toxicological effects by disrupting gut microbiome and immune homeostasis. <i>Journal of Immunotoxicology</i> , 2021 , 18, 93-104	3.1	1
16	Effect of the consumption of yacon flour and energy-restricted diet on glycation markers, and association between these markers and factors linked to obesity in adults with excess body weight: A randomized, double-blind, placebo-controlled clinical trial. <i>Nutrition</i> , 2021 , 91-92, 111395	4.8	1
15	Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome. <i>PLoS ONE</i> , 2013 , 8, e74302	3.7	35
14	The Close Interplay of Nitro-Oxidative Stress, Advanced Glycation end Products and Inflammation in Inflammatory Bowel Diseases. <i>Current Medicinal Chemistry</i> , 2020 , 27, 2059-2076	4.3	14
13	Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation. <i>Mini-Reviews in Medicinal Chemistry</i> , 2019 , 19, 1040-1048	3.2	7
12	Soluble Receptor for Glycation End-products Concentration Increases Following the Treatment of Severe Diabetic Ketoacidosis. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2020 , 12, 160-167	1.9	3
11	Glycation and Glycosylation in Cardiovascular Remodeling: Focus on Advanced Glycation End Products and O-Linked Glycosylations as Glucose-Related Pathogenetic Factors and Disease Markers. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2

10	Clinical Implications of Serum Biomarkers in Diabetic Cardiovascular Complications. <i>Korean Diabetes Journal</i> , 2009 , 33, 363		
9	Cardiovascular Complications in Renal Failure: Implications of Advanced Glycation End Products and Their Receptor RAGE. 2011 , 257-292		
8	Effects of Angiotensin-Converting Enzyme Polymorphism on Soluble Receptor for Advanced Glycation End-Products in Maintenance Hemodialysis Patients. <i>Korean Journal of Medicine</i> , 2013 , 85, 495	0.5	
7	Determinants of concentrations of N ^ε -carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancer. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2014 , 5, 152-63	0.9	8
6	Change of cardiovascular risk associated serologic biomarkers after gastric bypass: A comparison of diabetic and non-diabetic Asian patients.. <i>Asian Journal of Surgery</i> , 2022 ,	1.6	
5	Peripheral Transport Proteins Were Associated with 4-Year Cognitive Decline in APOE e4 Non-Carriers: A Longitudinal, Population-Based Study.. <i>Journal of Alzheimer's Disease</i> , 2022 ,	4.3	
4	Effects of Green Tea (-)-Epigallocatechin-3-Gallate (EGCG) on Cardiac Function - A Review of the Therapeutic Mechanism and Potentials.. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022 ,	3.2	1
3	Skin accumulation of advanced glycation end products and cardiovascular risk in Korean patients with type 2 diabetes mellitus. <i>Heliyon</i> , 2022 , e09571	3.6	1
2	Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study. <i>Cardiovascular Diabetology</i> , 2022 , 21,	8.7	1
1	High mobility group box 1 and Dickkopf-related protein 1 as biomarkers of glucose toxicity, atherogenicity, and lower cell function in patients with type 2 diabetes mellitus. 1-14		0